Brenus Pharma raised $25M in a Series A funding round led by Angelor to accelerate clinical trials for its precision cancer vaccines.
PRIVATESep 18, 2024
Amount Raised
$25 Million
Round Type
Series A
LyonBiotechnologyHealth CareTherapeutics
Investors
Stéphane LegasteloisJacques GardetteInvestsudNoshaqCrédit Agricole Centre EstCrédit Agricole Centre FranceUI InvestissementAngelor
Description
Brenus Pharma, a biotech company developing cancer vaccines, has completed a $25 million Series A financing round. This funding will fully support the first-in-human proof-of-concept for its STC-1010 cancer vaccine.
Who to call at Brenus Pharma, and when
A new round usually means Brenus Pharma is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Brenus Pharma raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Brenus Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Brenus Pharma. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Brenus Pharma
Location
Lyon, Auvergne Rhône Alpes, France
About
Brenus Pharma is a biotech company that specializes in the development of precision cancer vaccines. Their innovative technology platform, STC, utilizes an in-depth understanding of cancer complexity to create new treatment solutions. With a focus on transforming patient care, they aim to enhance immunotherapy outcomes for cancer patients. The company is dedicated to advancing its pipeline, featuring multiple candidates aimed at various solid tumor types.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Brenus Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LyonBiotechnologyHealth CareTherapeutics